Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 12/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 12/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675632 | 1.00 | LMNA (0.45) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL6675636 | 1.00 | LMNA (0.45) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL30811107 | 0.86 | BLM (0.53) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL28587727 | 0.86 | BLM (0.53) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL28587728 | 0.86 | BLM (0.53) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL30428628 | 0.80 | AKR1C3 (0.64) | LMNATSHRAKR1C3AKR1C2 | |
| SCHEMBL6679457 | 0.75 | CES2 (0.51) | RXRARXRBRXRGCES2CES1 | |
| SCHEMBL6679460 | 0.75 | CES2 (0.51) | RXRARXRBRXRGCES2CES1 | |
| SCHEMBL6701810 | 0.75 | CES2 (0.51) | RXRARXRBRXRGCES2CES1 | |
| SCHEMBL5609726 | 0.75 | UGT2B7 (0.44) | AKR1C3AKR1C2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| WO-2004037760-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKOXY-1-(TRIFLUOROMETHYL-SUBSTITUTED PHENYL)ETHANOL DERIVATIVES | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | ADH1A, ADH1C, ADH5 | LMNA 2286/4885MAPK1 234/4885BLM 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.